On June 28th, 2024, Alembic Pharmaceuticals Limited disclosed receiving final approval from the US Food & Drug Administration (USFDA) for its Doxycycline Capsules, 40 mg. Doxycycline Capsules treat inflammatory skin lesions (papules and pustules) caused by rosacea in adults. The approval means Alembic’s version is equivalent in effectiveness to the reference drug, Oracea Capsules, 40 …